Biomarkers in Alzheimer’s Disease Analysis by  Mass Spectrometry-Based Proteomics

Liu, Yahui; Qing, Hong; Deng, Yulin

doi:10.3390/ijms15057865

Cited by 51 publications

(30 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[18][19] There are suggestive evidences that changes in plasma or serum Aβ 40 , Aβ 42 , or the ratio of Aβ 42 /Aβ 40 may be associated with individuals at risk for developing AD. [20][21] Some studies, comparing clinically diagnosed AD patients with normal elderly individuals, showed no differences in either plasma Aβ 40 or Aβ 42 .…”

Section: Introductionmentioning

confidence: 99%

Serum concentration of beta amyloid peptide and the activity of angiotensin converting enzyme in alzheimers disease patients: search for a potential biomarker

2016

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Serum concentration of beta amyloid peptide and the activity of angiotensin converting enzyme in alzheimers disease patients: search for a potential biomarker

2016

View full text Add to dashboard Cite

“…Tau CSF levels have been measured with conventional methods such as enzyme-linked immunosorbent assay (ELISA), mass spectrometry or surface plasmon resonance, which are timeconsuming and/or expensive (Hye et al, 2014;Liu et al, 2014;Mehta et al, 2000;Sparks et al, 2012;Tuantranont, 2013). Researchers have made great efforts to generate rapid, cost-effective and highly sensitive detection tests using biosensors.…”

Section: Introductionmentioning

confidence: 99%

Detection of the tau protein in human serum by a sensitive four-electrode electrochemical biosensor

Wang

Acha

Shah

et al. 2017

Biosensors and Bioelectronics

View full text Add to dashboard Cite

This study presents a novel approach based on a four-electrode electrochemical biosensor for the detection of tau protein -one of the possible markers for the prediction of Alzheimer's disease (AD). The biosensor is based on the formation of stable antibody-antigen complexes on gold microband electrodes covered with a layer of a self-assembled monolayer and protein G. Antibodies were immobilized on the gold electrode surface in an optimal orientation by protein G interaction. Electrochemical impedance spectroscopy was used to analyze impedance change, which revealed a linear response with increasing tau concentrations. The assay is fast (<1 h for incubation and measurement) and very sensitive. The limit of quantification for the full-length 2N4R tau protein is 0.03 pM, a value unaltered when the assay was processed in bovine serum albumin or human serum. This technology could be adapted for the detection of other biomarkers to provide a multiple assay to identify AD progression in a point of care setting.

show abstract

“…Other than blood, cerebrospinal fluid (CSF), which directly interacts with the space of the brain and reflects biochemical changes that occurs in the brain, has also been used for the biomarker of dementia and AD. Proteins such as phospholipases A2, visinin-like 1, microtubule-associated protein tau, neurofilament proteins, and many more that were reviewed by Liu et al [70] have been considered as CSF biomarkers of AD. The increase in the generation of 2,4-dihydroxybutyrate with the progression of MCI was noted and considered as a promising biomarker of AD [51,71].…”

Section: Proteomic Biomarkers Of Dementiamentioning

confidence: 99%

“…Mass spectrometry-based proteomics has been widely used for biomarkers of dementia and AD [64]. Proteins such as Aβ40, Aβ42, and their ratio Aβ42:Aβ40 have been linked with AD and dementia [65].…”

Section: Proteomic Biomarkers Of Dementiamentioning

confidence: 99%

Proteomic Study of Degenerative Protein Modifications in the Molecular Pathology of Neurodegeneration and Dementia

Adav¹,

Sze²

2016

Update on Dementia

View full text Add to dashboard Cite

Dementia is a major public health burden, and the World Health Organization has identified this disorder as a major public health priority. There are limited treatment options due to poor understanding of key mechanism of dementia pathogenesis. Dementia has been regarded as a proteinopathy in which alterations of brain protein structure and function are the key features of the disorder. Proteinopathy can be triggered by degenerative protein modifications (DPMs), misfolding, aggregation, and deposition of the malformed proteins. Despite the clinical significance of alteration in protein abundances, DPMs, protein misfolding, and aggregation, the molecular mechanism that promotes these changes remains inadequately understood, mostly due to technical challenges. Proteomic is a powerful, sensitive, and advanced tool to study the progressive brain tissue damage that critically dysregulates key enzymes, accumulates modified proteins, and causes protein misfolding and aggregation, resulting in cognitive decline and dementia. The proteomic profiling of protein abundances and correlating DPMs with protein misfolding and aggregation have potential to elucidate underlying molecular mechanism of the disease. This chapter summarizes the recent proteomic developments for studying brain proteome, DPMs, and protein aggregation mechanism that may lead to dementia. We attempted to correlate DPMs and its impact on protein aggregation and deposition in brain tissues.

show abstract

Biomarkers in Alzheimer’s Disease Analysis by Mass Spectrometry-Based Proteomics

Cited by 51 publications

References 131 publications

Serum concentration of beta amyloid peptide and the activity of angiotensin converting enzyme in alzheimers disease patients: search for a potential biomarker

Serum concentration of beta amyloid peptide and the activity of angiotensin converting enzyme in alzheimers disease patients: search for a potential biomarker

Detection of the tau protein in human serum by a sensitive four-electrode electrochemical biosensor

Proteomic Study of Degenerative Protein Modifications in the Molecular Pathology of Neurodegeneration and Dementia

Contact Info

Product

Resources

About